Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-3-yl)-N-(3S)-3-piperidinyl-5-(trifluoromethyl)- manufacturers
- CDK7-IN-12
-
- $1980.00
-
2026-07-27
- CAS:2750638-94-7
- Purity:
- Supply Ability: 10g
|
| | Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-3-yl)-N-(3S)-3-piperidinyl-5-(trifluoromethyl)- Basic information |
| | Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-3-yl)-N-(3S)-3-piperidinyl-5-(trifluoromethyl)- Chemical Properties |
| density | 1.53±0.1 g/cm3(Predicted) | | pka | 15.02±0.30(Predicted) |
| | Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-3-yl)-N-(3S)-3-piperidinyl-5-(trifluoromethyl)- Usage And Synthesis |
| Uses | CDK7-IN-12 is a potent inhibitor of CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43)[1]. | | References | [1] Jing Wang, et al. Heterocyclic compounds and their derivatives. Patent WO2021249417A1. |
| | Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-3-yl)-N-(3S)-3-piperidinyl-5-(trifluoromethyl)- Preparation Products And Raw materials |
|